Documenta Ophthalmologica

, Volume 118, Issue 2, pp 81–88 | Cite as

Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections

  • Andreas Stahl
  • Nicolas Feltgen
  • Antje Fuchs
  • Michael BachEmail author
Original Research Article


Bevacizumab (Avastin®, Genentech) was one of the first anti-VEGF substances used to treat macular edema or choroidal neovascularization in patients with vascular ocular pathologies. However, only few studies evaluate the safety of intravitreal bevacizumab injections in regard to retinal photoreceptor function. We evaluated retinal function after repeated (2–3) monthly injections of bevacizumab in a prospective case series of 10 patients with various retinal diseases. Study endpoints were visual acuity (VA) using ETDRS charts and 3 full-field electroretinography sessions with a flash intensity range of 0.0005–2 cds/m2. V-log-I b-wave amplitudes were fitted by a Naka-Rushton model. No significant changes in scotopic or photopic ERG measures were observed between baseline ERG and last follow-up ERG. Individual patients showed transient alterations of ERG measures on the first follow-up visit. Mean visual acuity was stable over the time course of the study (logMAR = 0.42 at baseline and logMAR = 0.48 at last follow-up). In conclusion, three monthly repeated injections of bevacizumab do not affect mid-term electrophysiological retinal function. Transient alterations in ERG readings of individual patients 1 week after intravitreal bevacizumab injection may be attributed to short-term disruption of the retinal equilibrium through the trauma of injection. Evaluation of patients receiving more than three injections of anti-VEGF substances should be the focus of future studies.


Anti-VEGF Toxicity Bevacizumab Avastin Age-related macular degeneration ERG 



We thank Prof. Lutz L. Hansen and PD Dr. Hansjuergen Agostini for inspiration and advice.


  1. 1.
    Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372, e365Google Scholar
  2. 2.
    Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT et al (2007) Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27:439–444. doi: 10.1097/IAE.0b013e31804b3e15 PubMedCrossRefGoogle Scholar
  3. 3.
    Fulton AB, Rushton WA (1978) The human rod ERG: correlation with psychophysical responses in light and dark adaptation. Vision Res 18:793–800. doi: 10.1016/0042-6989(78)90119-0 PubMedCrossRefGoogle Scholar
  4. 4.
    Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG (2007) Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48:1773–1781. doi: 10.1167/iovs.06-0828 PubMedCrossRefGoogle Scholar
  5. 5.
    Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL et al (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279–284. doi: 10.1097/00006982-200603000-00005 PubMedCrossRefGoogle Scholar
  6. 6.
    Jaissle GB, Ziemssen F, Petermeier K, Szurman P, Ladewig M, Gelisken F et al (2006) Bevacizumab for treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 103:471–475. doi: 10.1007/s00347-006-1355-2 Google Scholar
  7. 7.
    Jorge R, Costa RA, Calucci D, Scott IU (2007) Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol 245:1045–1048. doi: 10.1007/s00417-006-0468-2 PubMedCrossRefGoogle Scholar
  8. 8.
    Lazarovici P, Marcinkiewicz C, Lelkes PI (2006) Cross talk between the cardiovascular and nervous systems: neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF)-implications in drug development. Curr Pharm Des 12:2609–2622. doi: 10.2174/138161206777698738 PubMedCrossRefGoogle Scholar
  9. 9.
    Lazic R, Gabric N (2007) Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245:68–73. doi: 10.1007/s00417-006-0466-4 PubMedCrossRefGoogle Scholar
  10. 10.
    Maturi RK, Bleau LA, Wilson DL (2006) Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26:270–274. doi: 10.1097/00006982-200603000-00003 PubMedCrossRefGoogle Scholar
  11. 11.
    Michels S (2006) Is intravitreal bevacizumab (Avastin) safe? Br J Ophthalmol 90:1333–1334. doi: 10.1136/bjo.2006.102293 PubMedCrossRefGoogle Scholar
  12. 12.
    Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea C, Loukianou E, Moschos M (2007) Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Multifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol 114:37–44. doi: 10.1007/s10633-006-9036-7 PubMedCrossRefGoogle Scholar
  13. 13.
    Ng EW, Adamis AP (2005) Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 40:352–368PubMedGoogle Scholar
  14. 14.
    Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK et al (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601–606. doi: 10.1016/j.ajo.2006.12.037 PubMedCrossRefGoogle Scholar
  15. 15.
    R Development Core Team (2007) R: A language and environment for statistical computing. Accessed 31 July 2006, from (
  16. 16.
    Severns ML, Johnson MA (1993) The care and fitting of Naka-Rushton functions to electroretinographic intensity-response data. Doc Ophthalmol 85:135–150. doi: 10.1007/BF01371129 PubMedCrossRefGoogle Scholar
  17. 17.
    Shetty R, Pai SA, Vincent A, Shetty N, Narayana KM, Sinha B, Shetty BK (2007) Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Doc Ophthalmol 116(2):129–135. doi:  10.1007/s10633-007-9090-9)Google Scholar
  18. 18.
    Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383–390. doi: 10.1097/00006982-200604000-00001 PubMedCrossRefGoogle Scholar
  19. 19.
    Stahl A, Agostini H, Hansen LL, Feltgen N (2007) Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 245:1429–1436. doi: 10.1007/s00417-007-0569-6 PubMedCrossRefGoogle Scholar
  20. 20.
    Wang Y, Galvan V, Gorostiza O, Ataie M, Jin K, Greenberg DA (2006) Vascular endothelial growth factor improves recovery of sensorimotor and cognitive deficits after focal cerebral ischemia in the rat. Brain Res 1115:186–193. doi: 10.1016/j.brainres.2006.07.060 PubMedCrossRefGoogle Scholar
  21. 21.
    Ziemssen F, Luke M, Messias A, Beutel J, Tatar O, Zrenner E, Bartz-Schmidt KU (2007) Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 28(2):101–109. doi:  10.1007/s10792-007-9122-1 Google Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Andreas Stahl
    • 1
  • Nicolas Feltgen
    • 1
  • Antje Fuchs
    • 1
  • Michael Bach
    • 1
    Email author
  1. 1.Universitäts-AugenklinikFreiburgGermany

Personalised recommendations